Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results from the Phase 2 TORREY Trial

Thursday, September 28, 2023 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the results of the Phase 2 TORREY Trial for Seralutinib, a treatment for Pulmonary Arterial Hypertension (PAH). The trial's findings indicate potential benefits of Seralutinib in managing this condition. The results are seen as a positive step forward in PAH treatment options.
Price reaction · baseline $0.7827 (2023-09-28T13:57:00.000Z) · hit during market hours · clean, no other GOSS news in the window
day 0 close · peak
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows promise for treating PAH.
  • Results from the Phase 2 TORREY Trial are encouraging.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results from the Phase 2 TORREY Trial
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib used for?

Seralutinib is used for the treatment of Pulmonary Arterial Hypertension (PAH).

What were the results of the TORREY Trial?

The Phase 2 TORREY Trial showed promising results for Seralutinib in managing PAH.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib Pulmonary Arterial Hypertension Phase 2 TORREY Trial clinical trial
Last updated: Sep 28, 2023

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →